This week's roundup of innovators includes Alfredo Arvide of MAP360, Gaurab Chakrabarti of Solugen, and Stephen Ives of YMCA of Greater Houston. Courtesy photos

Editor's note: The three innovators being called out this week for their latest news includes three leaders looking to make a difference and disrupt the norm. From innovating diversity and inclusion to making a huge splash in the chemicals industry.

Alfredo Arvide, CEO and co-founder of MAP360

This Houston startup is increasing access to marketing for other startups and small businesses

"We're here for the founders and the little guys," Alfredo Arvide says about his new venture that's redefining marketing for small businesses and startups. Photo courtesy of MAP360

Alfredo Arvide's story isn't too unfamiliar. After getting laid off amid a recession, he turned his full focus to his startup hoping to disrupt the industry he's worked in for years. The only difference here is Arvide's story is still ongoing, and the industry he's trying to disrupt is marketing for startups.

"There is a great opportunity in Houston with the accelerating innovation ecosystem," says Arvide. "When my co-founder and I were brainstorming ideas, we saw the need for a marketing program tailored specifically for startups or small businesses."

MAP360 touts a 50 percent or fewer costs of an agency with the same agency-quality talent. The services they offer range from branding, storytelling, design, to consulting. They also offer tiers or packages aimed for startups, funded or growing businesses, and established businesses. Click here to read more.

Gaurab Chakrabarti, CEO and co-founder of Solugen

Solugen, which uses plant-centered biotechnology to produce environmentally friendly chemicals, has raised an additional $30 million and is speculated to soon reach unicorn status. Photo via solugentech.com

Is Solugen going to be the next unicorn — a startup valued at $1 billion — to come out of Houston? That's what Forbes, but that's not what Gaurab Chakrabarti is focused on right now. He's got bigger goals to disrupt the entire chemicals industry.

"Quite simply, we want to become the next DowDuPont or the next iconic chemical company, but using principles of green chemistry instead of principles from petroleum chemistry," Chakrabarti says.

And he's on the right path. Recently, Solugen raised another $30 million in a bridge round after raising $36 million last year. Click here to read more.

Stephen Ives, president and CEO of the YMCA of Greater Houston

The Equity Innovation Center Powered by Reliant will have online resources as well as an interactive learning lab at Tellepsen Family Downtown YMCA. Photo courtesy of Urban Land Institute Houston

With Houston's diversity and in light of the current civil unrest, the YMCA of Greater Houston wanted to create something to help educate Houstonians and provide a space for unity and collaboration. That's why the organization is launching The Equity Innovation Center Powered by Reliant, says Stephen Ives, president and CEO of YMCA of Greater Houston.

"The YMCA of Greater Houston vows to stand with our brothers and sisters who are made to feel less safe by the many recent incidents – fighting for health equity in the face of the inequities being laid bare by the COVID-19 pandemic and unjust killings," says Ives. "The Y will continue expanding and strengthening its commitment to combat racism, bias, prejudice and inequalities while fighting for justice."

The center is coming out of a $100,000 donation from Reliant, which will be distributed in $50,000 commitments over two years. The sum is a part of Reliant and NRG's "Powering Change" initiative. Click here to read more.

"We're here for the founders and the little guys," Alfredo Arvide says about his new venture that's redefining marketing for small businesses and startups. Photo courtesy of MAP360

This Houston startup is increasing access to marketing for other startups and small businesses

A new Houston organization is working to redefine the way startups set up their marketing strategy — focusing on specific projects tailored to the client's goals at a significantly cheaper price than a normal marketing agency.

 MAP360, also known as The Marketing Acceleration Program, is collaborating one-on-one with clients to learn their particular needs and goals for individual projects. Unlike traditional marketing agencies, they do not work on retainer, instead they focus on small contracts to increase efficiency and affordability for startups and small businesses.

"There is a great opportunity in Houston with the accelerating innovation ecosystem," says Alfredo Arvide, CEO and co-founder. "When my co-founder and I were brainstorming ideas, we saw the need for a marketing program tailored specifically for startups or small businesses."

Arvide's new marketing acceleration program has always been one of his goals as a budding entrepreneur, previously founding Pushr an app that manages multiple social profiles across all platforms. However, it was his layoff from Accenture last month, a result of the ongoing impact of coronavirus on the economy, that spurred him into action with his business partner, Jacqueline Levine, who has taken on the role of chief marketing officer.

The two have combined decades of experience in the marketing world — most recently Arvide was the prototyping center director within the Houston Accenture Innovation Hub.

"Usually in a startup, the entrepreneur wears a lot of different hats," says Arvide. "They have the responsibility to market the business and manage financials, this is a lot of pressure. We wanted to provide a different sphere of the marketing spectrum at an affordable price."

MAP360 touts a 50 percent or fewer costs of an agency with the same agency-quality talent. The services they offer range from branding, storytelling, design, to consulting. They also offer tiers or packages aimed for startups, funded or growing businesses, and established businesses. Each package has a different time frame and helps the client's marketing goals with the most efficiency.

For example, a startup has a need for pitch materials and setting up basic brand guidelines, unlike a growing client who perhaps needs a marketing distribution plan or social media engagement plan more urgently.

"We are able to focus on affordability and the needs of our clients because of our strategic nature," says Arvide. "We are going to provide our clients with campaigns that are very specific to their audience while providing them a plan and metrics for success."

MAP360 strategy of upfront costs and marketing plans cut to size added another benefit for clients' bang for their buck with their proprietary approach to data. The psychographic data allows businesses to measure and meet their target metrics using a profile of their customer's interests and values.

"We use a partner firm that uses demographic and psychographic data," says Arvide. "Then we can analyze the firm's target audience at the highest probability. We are not casting a huge net, rather fishing for the very specific fish willing to bite."

A startup itself, MAP360 has its own plans and metrics for its own success, aiming to add 10 to 15 new clients before the end of the year and expect that figure to double in the next year to 20 to 30 clients. They also plan to use local marketing professionals and freelancers to expand their pool of specialists.

"We're here for the founders and the little guys," says Arvide. "We want to help them be better and partner with local talent to make Houston first in the innovation sphere."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.